Host: The Japanese Society of Toxicology
Pandemic of COVID-19 requires us to reduce physical contact and it accelerates using remote work instead of traditional working style at office. The field of clinical and non-clinical study is no exception. Under this situation, AI is a powerful tool to realize the remote work. LPIXEL has already developed 4 approved medical programs, EIRL Brain Aneurysm, EIRL Brain metry, EIRL Chest Nodule and EIRL Chest metry. More than 100 hospitals/clinics have already installed those 4 programs, and it means our programs is not proof of concept but it's timing for social implementation. Though in the field of diagnosis by medical images, teleradiology is getting popular as a method to work remotely, approved medical programs are expected as a method not only to avoid missed diagnosis but also to make doctors free from time limitation.
LPIXEL also tries to collaborate with several pharmaceutical companies and accelerate drug discovery by implementing AI. Our technology has been already implemented in the discovery phase and our target expand as pre-clinical phase.In the test of safety test of micronucleus, because our AI brings 0.85 correlation with visual inspection, it is expected to reduce test time. By expanding our AI as GLP grade, typical micronucleus can be found by AI and atypical ones are found by expert then, AI play important role to reduce total work time.
AI is promising to apply not only medical fields but also drug discovery, include the field of pre-clinical study. In this presentation we show our product as the case of social implementation and its possibility to expand at pre-clinical fields.
